Activities of Jiří MAŠTÁLKA related to 2016/2057(INI)
Shadow opinions (1)
OPINION on EU options for improving access to medicines
Amendments (5)
Amendment 39 #
Draft opinion
Paragraph 2
Paragraph 2
2. Considers that exclusive protection periods granted to pharmaceuticals through patents or other mechanisms hinder competition, lead to high prices and negatively impact access to needed medicines; observes that the EU´s current biomedical R&D system based on IP monopolies has proved a failure to deliver accessible and affordable lifesaving medicines, and that the EU has not received sufficient return on its public investment in biomedical R&D with regards to the property on the outcome of research;
Amendment 59 #
Draft opinion
Paragraph 4
Paragraph 4
4. Calls on the Commission to undertake a critical review of the impact of intellectual-property-related incentives on biomedical innovation, to explore alternatives to monopolies for the financing of medical R&D and to evaluate the functioning of the applicable limitations to patent allocations and to safeguard the right of countries to regulate and preserve policy space in order to guarantee universal access to medicines;
Amendment 75 #
Draft opinion
Paragraph 6
Paragraph 6
6. Calls on the Commission to encourage Member States to fully implement existing patent limitations and flexibilities when confronted with excessive pricing or abuse of monopoly rights; underlines the key role played by public investments in R&D and highlight the importance of implementing measures to ensure a public health return on investments when EU funds are financing medical R&D, including the provision of conditions attached to public R&D funding that ensure biomedical research results in suitable and affordable medicine;
Amendment 83 #
Draft opinion
Paragraph 7
Paragraph 7
7. Calls on the Commission to establish full transparency and public disclosure on the results of publicly financed R&D so that patenting and licensing conditions guarantee a public health return on public investments and reflect the structure of R&D funding.
Amendment 85 #
Draft opinion
Paragraph 7 a (new)
Paragraph 7 a (new)
7a. Stress the importance of developing a comprehensive access to medicines policy that ensures that all EU policies (global public health, development, research and trade) are consistent with, and beneficial for, access to affordable medicines for citizens in the EU and low-and middle-income countries alike, calls on the Commission to further explore the numerous tools providing new incentives for health technology innovation, such as mechanisms delinking the costs of research and development from the end product, as outlined by the World Health Organisation Global Strategy Plan of action (2008) and in the recent United Nations Secretary General's high level Panel on access to medicines - Promoting innovation and access to health technologies